Business
Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
Immuno-oncolytic virus replicates exclusively in tumor tissue and induces new T c...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of CancerImmuno-oncolytic virus replicates exclusively in tumor tissue and induces new T cell clonesDecrease in regulatory T cells leads to increased immune surveillance to fight cancerSAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 8, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced a poster presentation today at the annual meeting of the Society for Immunotherapy of Cancer (SITC), highlighting data from the AWARE-1 study in early breast cancer. The 34th Annual SITC Meeting is being held November 6-10, 2019 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.\"This is the first-time our biomarker data from AWARE-1 has been presented at a major academic conference,\" said Dr. Rita Laeufle, Chief Medical Officer of Oncolytics Biotech. \"The primary objective of this study is to evaluate changes in the immune environment of patients diagnosed with early stage breast cancer using our biomarker of T cell clonality measured by CelTIL score. This measures a change or expansion of infiltrating immune cells and importantly, an increase in CelTIL is known to correlate with a positive patient outcome. This initial data shows replication of pelareorep occurs exclusively in tumor tissue and there is an increase in CelTIL through the expansion of existing T cells, and most importantly, through the creation of new T cell clones. We continue to show that pelareorep changes the immunogenetic environment within the tumor, and the results of this early stage breast cancer study support our use of this biomarker and its value in predicting tumor response in our upcoming BRACELET-1 study in hormone receptor positive metastatic breast cancer.\"The next patient cohort to report from AWARE-1 focuses on patients receiving pelareorep and the standard of care, without Tecentriq. This cohort will allow for the comparison of patients treated with standard of care plus pelareorep, to patients receiving the standard of care, plus pelareorep, plus Tecentriq. This will be the first data from AWARE-1 to confirm the impact pelareorep has on enhancing the anti-tumor T cell response both on its own, and in com...